569
Views
5
CrossRef citations to date
0
Altmetric
Review

Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update

, , , , &
Pages 1235-1244 | Received 29 May 2018, Accepted 13 Jul 2018, Published online: 24 Jul 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Diana Prieto-Peña, Santos Castañeda, Belén Atienza-Mateo, Ricardo Blanco & Miguel A. González-Gay. (2021) Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Expert Review of Clinical Immunology 17:3, pages 225-232.
Read now
Rosanna Dammacco, Giovanni Alessio, Ermete Giancipoli, Patrizia Leone, Anna Cirulli, Leonardo Resta, Angelo Vacca & Franco Dammacco. (2020) Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements. Clinical Ophthalmology 14, pages 775-793.
Read now

Articles from other publishers (3)

Juan Pablo Vinicki, Oscar Gut, María del Rosario Maliandi, Jose Luis Velasco Zamora, Miguel Linarez, Maria Alejandra Cusa, Julio Got, Maria Andrea Spinetto, Adrian Jorge Estevez, Alejandro Brigante, Ana Carolina Curti, Ana Carolina Costi & Javier Cavallasca. (2023) Risk Factors for Relapse and/or Prolonged Glucocorticoid Therapy in Polymyalgia Rheumatica. JCR: Journal of Clinical Rheumatology Publish Ahead of Print.
Crossref
Jared Marc John & Rodney Daniel Sinclair. (2019) Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone. Australasian Journal of Dermatology 61:2, pages 170-171.
Crossref
Miguel Á. González-Gay, Trinitario Pina, Diana Prieto-Peña, Mónica Calderon-Goercke, Oreste Gualillo & Santos Castañeda. (2019) Treatment of giant cell arteritis. Biochemical Pharmacology 165, pages 230-239.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.